# EDGAR Filing Document

**Accession Number:** 0001604950
**File Stem:** 0001193125-25-242425
**Filing Date:** 2025-10
**Character Count:** 2806
**Document Hash:** 670bf86ac5bedae4d69bebe9bb5bc0d6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-242425.hdr.sgml**: 20251017

**ACCESSION NUMBER**: 0001193125-25-242425

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251017

**DATE AS OF CHANGE**: 20251017

**EFFECTIVENESS DATE**: 20251017

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** scPharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001604950
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 465184075
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38293
- **FILM NUMBER:** 251400634

**BUSINESS ADDRESS:**
- **STREET 1:** 25 BURLINGTON MALL ROAD, SUITE 203
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803
- **BUSINESS PHONE:** 617-517-0730

**MAIL ADDRESS:**
- **STREET 1:** 25 BURLINGTON MALL ROAD, SUITE 203
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 15** 

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION** 

**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)** 

**OF THE SECURITIES EXCHANGE ACT OF 1934.** 

**Commission File Number: 001-38293** 

## scPharmaceuticals Inc.
**(Exact name of registrant as specified in its charter)** 

**25 Mall Road, Suite 203** 

**Burlington, Massachusetts 01803** 

**(617) 517-0730** 

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

**Common Stock, par value $0.0001 per share** 

**(Title of each class of securities covered by this Form)** 

**None** 

**(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)** 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
|  Rule 12g-4(a)(1) | ☒ |
|  Rule 12g-4(a)(2) | ☐ |
|  Rule 12h-3(b)(1)(i) | ☒ |
|  Rule 12h-3(b)(1)(ii) | ☐ |
|  Rule 15d-6 | ☐ |
|  Rule 15d-22(b) | ☐ |

---

Approximate number of holders of record as of the certification or notice date: One (1) holder.

------

Pursuant to the requirements of the Securities Exchange Act of 1934, scPharmaceuticals Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
|  | **scPharmaceuticals Inc.** | **scPharmaceuticals Inc.** |
|  | By: | */s/ David Thomson* |
|  | Name: | David Thomson |
|  | Title: | Secretary |
| Date: October 17, 2025 |  |  |

---